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ABSTRACT
Globally, the prevalence of Klebsiella pneumoniae (K. pneumonia) producing 
extended spectrum beta lactamase (ESBL) has been increasing steadily. The 
susceptibility patterns of ESBL-producing K. pneumonia varies considerably 
among countries. Therefore, the investigation of ESBL-producing K. 
pneumoniae in clinical isolates and their susceptibility are warranted. This 
research aimed to determine the proportion of ESBL-producing K. pneumoniae 
and the antibiotic susceptibility patterns of clinical isolates from Dr. Soeradji 
Tirtonegoro General Hospital, Klaten, Central Java. Identification of K. 
pneumoniae was performed by analyzing colony morphology, microscopic 
examination, and biochemical testing using Microbact. Both antibiotic 
susceptibility testing and ESBL screening (using ceftazidime, cefotaxime, and 
ceftriaxone discs) were conducted using disc diffusion method according to 
CLSI. The positive results were confirmed with modified double disk synergy 
(MDDST) using amoxicillin-clavulanate, ceftazidime, cefotaxime, and cefepime 
discs. From 962 clinical bacterial isolates, 168 (17.46%) isolates were identified 
as K. pneumoniae, during June 2017-May 2018. K. pneumoniae was mainly 
isolated from the Intensive Care Units (ICU) (29.17%) and with sputum being the 
most common specimen (45.24%). Overall ESBL producers were 52.98%, with 
the majority from ICU (41.57%) and isolated from sputum specimens (40.45%). 
ESBL-producing K. pneumoniae showed high resistance to many antibiotics. 
The sensitivity of ESBL-producing K. pneumoniae isolated from respiratory 
tract samples against piperacillin-tazobactam, amikacin, and meropenem 
was more than 80%. In conclusion, among all K. pneumoniae isolates, ESBL K. 
pneumoniae was 52.98%. ESBL K. pneumoniae from respiratory tract specimens 
had a sensitivity of more than 80% against piperacillin-tazobactam, amikacin, 
and meropenem.
ABSTRAK
Prevalensi Klebsiella pneumoniae (K. pneumonia) yang menghasilkan extended 
spectrum beta lactamase (ESBL) telah meningkat terus-menerus secara 
global. Pola kerentanan K. pneumonia penghasil ESBL sangat bervariasi di 
antara negara-negara di dunia. Oleh karena itu diperlukan penyelidikan K. 
pneumoniae penghasil ESBL pada isolat klinis dan kerentanannya. Penelitian 
ini bertujuan untuk menentukan proporsi K. pneumonia yang memproduksi 
ESBL dan pola kerentanan antibiotik isolat klinis dari Rumah Sakit Dr. Soeradji 
Tirtonegoro Klaten, Jawa Tengah. Identifikasi K. pneumoniae dilakukan 
dengan menganalisis morfologi koloni, pemeriksaan mikroskopis, dan 
pengujian biokimia menggunakan Microbact. Kedua uji kerentanan antibiotik 
dan skrining ESBL (menggunakan cakram ceftazidim, cefotaksim, dan 
ceftriakson) dilakukan dengan menggunakan metode difusi cakram menurut 
CLSI. Hasil positif dikonfirmasi dengan modified double disk synergy (MDDST) 
menggunakan amoksisilin-klavulanat, ceftazidim, cefotaksim, dan cakram 
cefepim. Dari 962 isolat bakteri klinis, 168 (17,46%) isolat diidentifikasi sebagai 
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K. pneumoniae, selama Juni 2017-Mei 2018. K. pneumoniae terutama diisolasi 
dari intensive care unit (ICU) (29,17%) dan dengan dahak sebagai spesimen 
umum (45,24%). Secara keseluruhan produsen ESBL adalah 52,98%, dengan 
mayoritas dari ICU (41,57%) dan diisolasi dari spesimen dahak (40,45%). 
K. pneumonia yang memproduksi ESBL menunjukkan resistensi tinggi 
terhadap banyak antibiotik. K. pneumoniae penghasil ESBL yang diisolasi dari 
sampel saluran pernapasan menunjukkan sensitivitas terhadap piperasilin-
tazobactam, amikasin, dan meropenem lebih dari 80%. Dapat disimpulkan di 
antara semua isolat K. pneumoniae, ESBL K. pneumoniae adalah 52,98%. ESBL 
K. pneumoniae dari spesimen saluran pernapasan memiliki sensitivitas lebih 
dari 80% terhadap piperasilin-tazobaktam, amikasin, dan meropenem.
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INTRODUCTION
Klebsiella pneumoniae is one 
of the bacteria with a high level of 
antibiotic resistance and often causes 
nosocomial infections in hospitals.1,2 
Klebsiella pneumoniae is known 
to cause pneumonia, urinary tract 
infection (UTI), bacteremia, liver 
abscess, wound infection, intravascular 
infection, bile duct infection, peritonitis, 
rhinoscleroma meningitis, ozaena, 
sinusitis, otitis, enteritis, appendicitis, 
cholecystitis, pyogenic brain abscess, and 
endophthalmitis.2–5 It is often isolated 
from ICUs and associated with outbreaks 
in hospitals.6
Extended spectrum beta-lactamase 
(ESBL) is a mutated β lactamase enzyme 
capable of hydrolyzing penicillin, first, 
second, third and fourth generation 
cephalosporin, and monobactam but 
cannot hydrolyze cephamycins or 
carbapenem .7 ESBL encoding genes 
are frequently found on the same 
plasmids that encode resistance 
to aminoglycosides, sulfonamides, 
and fluoroquinolones, so that ESBL-
producing bacteria are commonly 
multidrug-resistant (MDR) bacteria.8 
Various studies have shown an 
increased prevalence of ESBL-producing 
K. pneumoniae worldwide. Data from the 
tigecycline evaluation and surveillance 
trial (TEST) during January 2004 to 
August 2006 showed ESBL-producing 
K. pneumoniae in Latin America (44%), 
Asia (22.4%), Europe (13.3%), and 
North America (7.5%) respectively.9 In 
China, ESBL-producing K. pneumoniae 
was reported 31.8% of K. pneumoniae 
during August 2010-2011.10 Meanwhile 
the prevalence of ESBL-producing 
K. pneumoniae in Iran was 43% of K. 
pneumoniae during 2007-200811 and in 
Tanzania it was 63.73% of K. pneumonia.12
The prevalence of ESBL-producing K. 
pneumoniae in Indonesia was reported 
differently. At Dr. Soetomo General 
Hospital, Surabaya, the prevalence 
of ESBL-producing K. pneumoniae 
was reported 35.35% during January 
2005-April 200513; 23% during January-
June 2010; 50.28% during January-
November 2011; 58% during July-
December 2012, and 38.5% during 
October 2014-May 2015.14,15 Meanwhile 
the prevalence of ESBL-producing K. 
pneumoniae was reported 66.2% at 
Dr. Arifin Achmad General Hospital, 
Pekanbaru during January-December 
2015.16
ESBL-producing bacteria are a major 
concern because they are associated 
with MDR microbes, which cause limited 
choices of antibiotics for the treatment 
of infections leading to increased 
morbidity, mortality and hospital costs.17 
Thus, the detection of ESBL-producing 
K. pneumoniae is important for optimal 
patient therapy choices and outcomes.
Screening of ESBL-producing K. 
pneumoniae can be done by disk diffusion 
using ceftazidime, cefotaxime, and 
ceftriaxone discs in accordance with the 
clinical laboratory standards institute 
(CLSI) M100 28th Edition.18 This should 
be followed by a confirmation test with 
the modified double disk synergy test 
(MDDST) using ceftazidime, cefotaxime, 
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cefepime, and amoxicillin-clavulanate 
discs.19,20
The globally increasing prevalence 
of ESBL-producing K. pneumoniae 
infections, the increasing incidence of 
antibiotic resistance, and the increasing 
morbidity and mortality due to MDR 
bacterial infections in hospitals, prompt 
researchers to investigate ESBL-
producing K. pneumoniae clinical isolates 
and their antibiotic sensitivity pattern. 
This research aimed to determine 
the proportion of ESBL-producing 
K. pneumoniae and the antibiotic 
susceptibility patterns of clinical isolates 
from Dr. Soeradji Tirtonegoro General 
Hospital, Klaten, Central Java.
MATERIALS AND METHODS
Study design and data collection
This was a cross-sectional descriptive 
study using secondary data from the 
archive of culture and susceptibility 
testing results at the Clinical Microbiology 
Laboratory Dr. Soeradji Tirtonegoro 
General Hospital, Klaten, Central Java 
during June 2017-May 2018. Screening 
and confirmation of ESBL-producing 
K. pneumoniae was conducted in the 
Microbiology Laboratory of the Faculty 
of Medicine, Public Health and Nursing, 
Universitas Gadjah Mada, Yogyakarta, 
Indonesia. The research protocol was 
approved by The Medical and Health 
Research Ethics Committee, Faculty of 
Medicine, Public Health and Nursing, 
Universitas Gadjah Mada with number 
KE/FK/0784/EC/2018.
Subjects
The subjects of the study were K. 
pneumoniae samples isolated from 
various clinical specimens of patients 
at Dr. Soeradji Tirtonegoro General 
Hospital, Klaten, Central Java during 
June 2017-May 2018.
Isolation, identification, and antibiotic 
susceptibility test (AST)
Clinical specimens were inoculated 
on blood agar and Mac Conkey agar 
(Oxoid, UK). All incubations were 
conducted aerobically at 370 C for 18-24 
hours.6 Identification of K. pneumoniae 
isolates was based on the morphology 
of colonies on blood agar and Mac 
Conkey, microscopic examination with 
gram stain4,21 and biochemical test 
using MicrobactTM GNB 24E (Oxoid, 
UK). Biochemical tests were conducted 
according to company instructions.
K. pneumoniae isolates were tested 
for their AST by the disc diffusion method 
in accordance to CLSI guideline.18 The 
following antibiotic discs from Oxoid, 
United Kingdom were used accordingly: 
cephazolin (30µg), gentamicin (10µg), 
tobramycin (10µg), amikacin (30µg), 
amoxicillin-clavulanate (20/10µg), 
piperacillin-tazobactam (100/10µg), 
cefuroxime (30µg), cefepime (30µg), 
ceftriaxone (30µg), ciprofloxacin (5µg), 
levofloxacin (5µg), meropenem (10µg), 
nitrofurantoin (100µg), trimethoprim-
sulfamethoxazole (25µg), cefotaxime 
(30µg), and ceftazidime (30µg). Sensitive 
or resistant determination was based on 
CLSI references (18). Antibiotics were 
used according to the panel of agreement 
from the Indonesian Society for Clinical 
Microbiologist of 2015 based on CLSI 
references.
Screening and confirmation of ESBL-
producing K. pneumoniae
ESBL-producing K. pneumoniae 
screening was done with ceftriaxone, 
cefotaxime, and ceftazidime discs (Oxoid, 
UK) based on CLSI references.18 The 
confirmation test of ESBL-producing K. 
pneumoniae was done using amoxicillin-
clavulanate (20/10 µg) disc along with 
ceftazidime 30 μg, cefotaxime 30 μg, 
and cefepime 30 μg discs (Oxoid, UK). A 
lawn culture of the organisms was made 
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on a Mueller Hinton (MH) agar plate, 
as recommended by CLSI. Amoxicillin-
clavulanate (20/10 µg) disc was placed 
in the center of the plate. The discs of 
ceftazidime 30 μg, cefotaxime 30 μg, and 
cefepime 30 μg were placed center to 
center to amoxicillin-clavulanate disc 20 
mm apart. Then MH agar was incubated 
for 18-24 hours at 370C. Any distortion or 
increase in the zone towards the disc of 
amoxicillin-clavulanate was considered 
as positive for the ESBL production.19,20
RESULTS
During June 2017-May 2018, 168 
(17.46%) of K. pneumoniae isolates were 
isolated from 962 total clinical bacterial 
isolates at Dr. Soeradji Tirtonegoro 
General Hospital Klaten, Central Java. 
The K. pneumoniae isolates were mainly 
obtained from patients treated in the 
intensive care unit (29.17%) (TABLE 1), 
and isolated from sputum specimens 
(45.24%) (TABLE 2).
TABLE 1. Specimen locations [n (%)]of K. pneumoniae isolates at Dr. Soeradji 
Tirtonegoro General Hospital, Klaten during June 2017-May 2018
Specimen locations
K. pneumoniae 
isolates (n=168)
ESBL producing 
K. pneumoniae isolates 
(n=89)
Intensives Care Unit 49 (29.17) 37 (41.57)
•	 Adults 27 (16.07) 16 (17.98)
•	 Children and Neonates 22 (13.10) 21(23.60)
Non-Surgery ward 37 (22.02) 10 (11.24)
Pulmonary ward 24 (14.29) 9 (10.11)
Surgery ward 23 (13.69) 11(12.36)
Pediatric ward 16 (9.52) 11 (12.36)
Perinatology ward 11 (6.55) 6 (6.74)
Clinic 7 (4.17) 5 (5.62)
Obstetrics and Gynecology ward 1 (0.60) 0 (0)
TABLE 2. Distribution of specimen types [n (%)] for isolating K. pneumoniae at Dr 
Soeradji Tirtonegoro General Hospital Klaten during June 2017-May 2018
Types of specimen
ESBL-producing 
K. pneumoniae 
isolates (n=89)
K. pneumoniae 
isolates (n=168)
Proportion ESBL-produc-
ing K. pneumoniae (%)
Sputum 36 (40.45) 76 (45.24) 36/76 (47.36)
Pus 12 (13.48) 27 (16.07) 12/27 (44.44)
Blood 18 (20.22) 20 (11.90) 18/20 (90)
Urine 8 (8.99) 12 (7.14) 8/12 (66.67)
Bronchial washings 1 (1.12) 9 (5.36) 1/9 (11.11)
Feces 5 (5.62) 6 (3.57) 5/6 (83.33)
Wound swab 3 (3.37) 5 (2.98) 3/5 (60)
Sterile site 2 (2.25) 7 (4.17) 2/7 (28.57)
Others* 4 (4.49) 6 (3.57) 4/6 (66.67)
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Out of 168 isolates of K. pneumoniae, 
104 isolates were possible ESBL 
producers (61.90%), with 85.58% (89/104) 
confirmed as ESBL producers using 
the MDDST method (FIGURE 1). The 
proportion of K. pneumoniae confirmed 
as ESBL producers was 52.98% (89/168) 
of the total isolates of K. pneumoniae. 
ESBL-producing K. pneumoniae were 
mostly obtained from patients treated in 
the ICU (41.57%) (TABLE 1).
A B C
FIGURE 1. A positive MDDST for cephalosporin discs; A) A positive MDDST 
with an increased inhibition zone for ceftazidime, cefotaxime and 
cefepime towards amoxicillin clavulanate; B) A positive MDDST 
with increased inhibition zone for cefotaxime and cefepime; 
C) A positive MDDST with increased inhibition zone only for 
cefepime. AMC=amoxicillin clavulanate; CAZ=ceftazidime; CTX= 
cefotaxime; FEP=cefepime; CN=gentamicin
Based on the distribution of 
specimen types, ESBL-producing K. 
pneumoniae was mostly isolated from 
sputum (40.45%) (TABLE 2). Whereas 
if based on the proportion of ESBL 
producers, these isolates were often 
found in all specimens except those 
originating from bronchial washings. 
The proportion of ESBL-producing K. 
pneumoniae in sputum, pus, blood, and 
urine was 47.36%, 44.44%, 90% and 
66.67%, respectively (TABLE 2).
TABLE 3 shows the percentage 
susceptibility of ESBL-producing K. 
pneumoniae clinical isolates to various 
origin specimens using antibiotic panels 
according to the Indonesian Society for 
Clinical Microbiologist. In this study, 38 
isolates of K. pneumoniae were derived 
from respiratory tract specimens, 
namely sputum, bronchial washings, 
and tracheal aspiration. ESBL-producing 
K. pneumoniae from respiratory tract 
specimens had a sensitivity of more than 
80% to piperacillin-tazobactam (88.89%), 
amikacin (97.37%), and meropenem 
(100%). Sensitivity to cefepime and 
ceftriaxone were 0% in each.
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TABLE 3. Percentage of susceptibility (%) of ESBL-producing K. 
pneumoniae isolates to antibiotics based on the origin 
of specimens at Dr. Soeradji Tirtonegoro General 
Hospital Klaten during June 2017-May 2018
The origin of the specimens
Antibiotics Respiratory 
tracts (n=38)
Blood
(n=18)
Wound
(n=17)
Urine
(n=8)
Cephazolin 0 - 11.76 0
Gentamycin 34.21 11.11 64.71 37.5
Tobramycin# 26.32 16.67 35.29 37.5
Amikacin# 97.37 100 82.35 87.50
Amoxicillin- Clavu-
lanate 28.95 - 58.82 12.50
Piperacillin- Tazo-
bactam# * 88.89 75 75 100
Cefuroxime 2.63 0 5.88 0
Cefepime# 0 0 0 0
Ceftriaxone 0 0 5.88 0
Ciprofloxacin - 66.67 17.65 62.50
Levofloxacin# 71.05 83.33 29.41 75
Meropenem# 100 100 100 100
Trimethoprim- Sul-
famethoxazole 18.42 - 11.76 25
Nitrofurantoin - - - 75
*Not all ESBL-producing K. pneumoniae isolates were tested with 
piperacillin-tazobactam discs. The number of ESBL-producing K. 
pneumoniae isolates tested with piperacillin-tazobactam in the 
respiratory tract = 9, blood = 4, wounds = 4, urine = 1; #Antibiotics 
with restricted use based on Indonesian Society for Clinical 
Microbiologist.
DISCUSSION
In this study, the proportion of K. 
pneumoniae isolates was 17.46% of total 
clinical bacterial isolates during June 
2017-May 2018. This finding should be 
a major concern because K. pneumoniae 
is often associated with high levels 
of antibiotic resistance, nosocomial 
infections, and outbreaks in hospital.6
The ESBL-producing K. pneumoniae 
was mostly isolated from sputum. This is 
in line since K. pneumoniae often causes 
pneumonia, septicemia, UTI and wound 
infections.22 The same results were also 
reported from Dr. Arifin Achmad General 
Hospital Pekanbaru,16 whereas research 
at Bugando Medical Center Tanzania 
reported that the pathogen originated 
mostly from urine.12
The majority of infections caused 
by K. pneumoniae are associated with 
hospitalization, especially in ICUs.6 
In this study, ESBL-producing K. 
pneumoniae was mostly isolated from 
patients treated in the ICU. Similar 
results were also reported at Dr. Arifin 
Achmad General Hospital Pekanbaru.16 
and Imam Reza Hospital of Mashhad 
Iran.11 ESBL-producing K. pneumoniae 
are mainly obtained from ICUs for adults, 
neonates and premature infants.12 
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Accordingly, ICU is one of the risk factors 
of ESBL infection, because patients 
in intensive care unit are often given 
long-term broad-spectrum antibiotics, 
invasive procedures, and long-term 
catheter placements. Other risk factors 
are pressure sores, poor nutritional 
status, and travel history to Asia, Greece, 
Turkey, and the United States.11,23-26
In this study, the ESBL confirmation 
test was done with MDDST, which is a 
modification of the Double Disc Synergy 
Test (DDST) to increase sensitivity to 
bacteria that co-produce AmpC and 
ESBL enzymes. Many of K. pneumoniae 
isolates are able to produce both of 
those enzymes. 27 AmpC β lactamase 
hydrolyzes penicillins, cephalosporins, 
cephamycins, and monobactams 
but does not inhibit clavulanate. 28 
Clavulanate induces high levels of AmpC 
expression in bacteria with AmpC and 
ESBL co-production, thereby hydrolyzing 
third generation cephalosporins. 
AmpC expression covers the synergy of 
third generation cephalosporins with 
amoxicillin-clavulanate.23
High level AmpC expression has 
minimal effect on cefepime, so that an 
increase in the inhibition zone between 
amoxicillin-clavulanate and cefepime 
discs can still be observed. If the synergy 
effect is only positive for cefepime but 
has a negative effect on third generation 
cephalosporins, isolates are suspected 
of co-production of AmpC and ESBL 
(20). MDDST using ceftazidime 30 µg, 
cefotaxime 30 μg, and cefepime 30 μg, 
has a sensitivity of 100% and specificity 
of 93%.19
After confirmation testing, most 
of the K. pneumoniae isolates were 
identified as ESBL producers with 
ceftazidime, cefotaxime, and cefepime 
discs. Only a small number of isolates 
were confirmed as ESBL producers with 
cefotaxime or cefepime discs, because 
the optimal substrate profile varied 
among the ESBL enzymes.29
In this study, the proportion of 
ESBL-producing K. pneumoniae isolates 
was 52.98%. The proportion of ESBL-
producing bacteria is important to know 
because it correlates with an increase 
in antibiotic resistance. This causes 
limited choice of antibiotics. Sensitivity 
patterns of ESBL producing bacteria 
can help clinicians determine the right 
antibiotic for therapy. Similar results 
were reported from Dr. Soetomo General 
Hospital, Surabaya in 2011 (50.28%) and 
in 2012 (58%).14 While higher yields 
were reported from Dr. Arifin Achmad 
General Hospital, Pekanbaru in 2015 
(66.2%).16 The difference in this study 
findings might be due to differences 
in ESBL detection methods, sampling 
techniques, study population, patient 
characteristics, guidelines for antibiotic 
use and infection control strategies.11,13,15
The number of ESBL producing 
bacteria is one indicator for the 
observation of outbreaks of MDR 
bacteria.30 The high number of ESBL- 
producing K. pneumoniae among various 
hospitals in Indonesia, shows the large 
role of ESBL bacteria in antibiotic 
resistance. Evaluation of antibiotic 
usage and surveillance of MDR bacteria 
must be routinely done and reported 
periodically by the local Antimicrobial 
Stewardship Team in the relevant 
hospital.30 Regulations are needed related 
to compliance with prudent antibiotic 
usage, especially cephalosporins.31 
In addition, compliance with the 
principle of standard precautions must 
be increased to prevent the spread of 
resistant bacteria through plasmids.32
Controlling the spread of ESBL-
producing bacteria is done by identifying 
and immediately isolating patients with 
suspected ESBL-producing bacteria 
colonization or infection, conducting 
molecular epidemiological analyzes on 
strains of colonized or infected patients,23 
and also minimizing the length of 
treatment to reduce the likelihood 
of patients being a source of cross 
infection.33 The spread of pathogens 
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and the risk of cross infection can be 
minimized by placing infected patients 
in isolation rooms. If the isolation room 
is not available, the patient should be 
placed in a cohorting way, which involves 
treating several patients with the same 
pattern of infection in one room.30
Precautions should always be applied 
since the proportion of ESBL- producing 
K. pneumoniae is high in sputum, pus, 
blood and urine. The principle of 
standard precautions must be done 
especially in hospitalized patients to 
avoid nosocomial infections. Lower 
respiratory tract infections should be of 
particular concern, especially in patients 
using endotracheal tubes.31 Likewise, the 
use of an intravenous catheter, arterial 
catheter and urinary catheter should 
also be a concern for septicemia and 
urinary tract infection.
The results of bacterial sensitivity 
testing for antibiotics can be arranged 
into an antibiogram for empirical 
therapy guidelines. Antibiogram 
contains isolate data according to the 
type of specimen and room location.30 
The number of isolates needed to make 
the ideal antibiogram is at least 30.34 In 
this study, the data that can be used was 
ESBL-producing K. pneumoniae isolates 
originating from the respiratory tract. 
Antibiotics that have a sensitivity of 
more than 80% can be used as empirical 
therapy.30
ESBL-producing K. pneumoniae 
isolates originating from the respiratory 
tract have a sensitivity of more than 
80% against amikacin, piperacillin 
tazobactam, and meropenem. Although 
piperacillin-tazobactam has a sensitivity 
of more than 80%, not all isolates 
of K. pneumoniae originating from 
the respiratory tract were tested for 
sensitivity to piperacillin-tazobactam. 
So, it needs special consideration for 
piperacillin-tazobactam to be used as 
empirical therapy.
ESBL-producing K. pneumoniae 
isolates originating from other specimens 
are less than 30 isolates each. Therefore, 
the results of sensitivity must be 
interpreted with special consideration. 
The sensitivity data of less than 30 
isolates may cause an unreliable and 
unrepresentative antibiogram.34
The sensitivity of ESBL-producing K. 
pneumoniae with more than 80% were 
obtained for ertapenem, meropenem, and 
amikacin at Dr. Arifin Achmad General 
Hospital, Pekanbaru in 2015.16 Whereas 
amikacin, cefoperazone-sulbactam, 
meropenem and phosphomycin were 
antibiotics which are reported to have 
a sensitivity of more than 80% in Dr. 
Soetomo Hospital Surabaya, Dr. Saiful 
Anwar General Hospital, Malang, and 
Dr. Kariadi General Hospital, Semarang 
in 2010.31 This means an antibiotic 
choice with good sensitivity, is limited 
to antibiotics which are restricted such 
as meropenem, piperacillin-tazobactam, 
and amikacin.
Carbapenem is the treatment of 
choice for severe infections caused 
by ESBL-producing K. pneumoniae.35 
However, the increasing incidence of 
infection with ESBL-producing bacteria 
throughout the world, has led to an 
increase in the use of carbapenem. 
The use of excessive carbapenem 
triggers selection pressure resulting 
in carbapenem resistant bacteria.2 
Carbapenem resistance causes antibiotic 
resistance problems which are more 
difficult to overcome.
This study has limitations due to 
the scarcity of piperacillin-tazobactam 
discs. Not all K. pneumoniae isolates 
were tested for antibiotic susceptibility 
with piperacillin-tazobactam so that 
representative sensitivity data were not 
available.
CONCLUSION
Proportion of ESBL-producing K. 
pneumoniae clinical isolates is 52.98% of 
total K. pneumoniae isolates at Dr. Soeradji 
Tirtonegoro General Hospital, Klaten. 
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Piperacillin-tazobactam, amikacin, and 
meropenem have a sensitivity of more 
than 80% in the respiratory tract sample 
isolates from patients at Dr. Soeradji 
Tirtonegoro General Hospital, Klaten.
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